Source: http://patentcircle.blogspot.hk/2007/11/
Timestamp: 2017-10-20 14:30:19
Document Index: 608684030

Matched Legal Cases: ['Application No. 3834', 'Application No. 329', 'Application No. 330', 'Application No. 331', 'Application No. 332', 'Application No. 3313']

patent circle: November 2007
3834/CHENP/2007A: Human Monoclonal Antibodies
International Application No. PCT/US06/03644 by University of Massachusetts has lately entered into Indian National Phase and published as Application No. 3834/CHENP/2007A for HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF. The National Phase Application is filed on September 03, 2007 claiming priority from International Application (published as WO2006/084006) filed February 02, 2005.
Posted by Varun Chhonkar on 3:11:00 PM No comments:
Avestha Files Indian Patent Applications for DPP inhibitors
Bangalore-based Avestha Gengraine Technologies Pvt. Ltd. lately got published five of its patent applications for dipeptidyl peptidase inhibitors filed with the Chennai Patent Office. Details of these applications are as follows.
Application No. 329/CHE/2006A titled “Nananoic acid derivatives as dipeptidyl peptidase inhibitors” filed February 27, 2006.
Application No. 330/CHE/2006A titled “Octanoic acid derivatives as dipeptidyl peptidase inhibitors” filed February 27, 2006.
Application No. 331/CHE/2006A titled “Hexanoic acid derivatives as dipeptidyl peptidase inhibitors” filed February 27, 2006.
Application No. 332/CHE/2006A titled “Ethanoic acid derivatives as dipeptidyl peptidase inhibitors” filed February 27, 2006.
Application No. 3313CHE/2006A titled “Heptanoic acid derivatives as dipeptidyl peptidase inhibitors” filed February 27, 2006.
Posted by Varun Chhonkar on 2:56:00 PM No comments:
Dear Readers: Vote for Legallyours
Legal Process Outsourcing (famously known as Legallyours) has been selected by the ABA Journal as one of the 100 best websites for lawyers, which invite readers to vote for their favorite legal blog (voting will continue until January 02, 2008). Your invaluable vote can make Legallyours the best legal blog. PatentCircle humbly requests its Readers to take out a moment from their invaluable time and vote for Legalllyours. To vote, please click on http://www.abajournal.com/blawgs/blawg100/toolkit, scroll down to about 80% of the page or search for "Rahul" and click on the vote button adjacent to the blog mention. Thanks for your support! Patent Circle
Posted by Varun Chhonkar on 10:20:00 AM No comments:
PCT Application for Ritonavir Polymorph Enters Indian National Phase
Illinois-based healthcare company Abbott Laboratories has lately filed a National Phase Application # 1638/MUMNP/2007A for a new crystalline polymorph of Ritonavir, maturing from its PCT Application # PCT/1999/16334 published as WO 2000/004016 (the ‘016 publication) dated January 27, 2000. The National Phase Application claims its earliest priority from the US Application # 09/119,345 filed July 20, 1998. The ‘016 publication claims a crystalline polymorph (designated as Form II), a substantially pure amorphous form of Ritonavir and processes for the preparation. The crystalline Form II is obtained by treating amorphous Ritonavir with a C1-C3 alcohol, preferably anhydrous alcohol, or by recrystallization of Form I or mixtures of Form I and Form II from a solution in a suitable solvent, with seeding with Form II crystals, followed by addition of an anti-solvent. The substantially pure amorphous form is prepared from the Form I crystalline polymorph by melting Form I and rapidly cooling the melt, isolating the resulting solid provides amorphous Ritonavir, or by slowly adding a solution of Form I in a suitable solvent to an anti-solvent/water, followed by isolation of the resulting solid, or by lypophilization of a solution of Form I. The National Phase Application is divisional application of earlier filed National Phase Application # IN/PCT/2001/0018/MUMA. It seems to be that Abbott bifurcated crystalline polymorph of Ritonavir and Substantially pure amorphous Ritonavir into two applications.
Posted by Varun Chhonkar on 1:04:00 PM No comments:
Granted patents in India on November 23, 2007 (Pharmaceutical /Biotech related Inventions)
GrantedPatent No :
136/DEL/2000
"Vasoactive Intestinal Peptide Analogs"
196/DEL/2000
"A Process For The Preparation Of Alkyl 3-
Cyclopropylamino-2-[2,4-Dibromo-3-(Difluoromethoxy) Benzoyl]-2-Propenoate"
"Oral Antispasmodic Anti-inflammatory Composition Comprising Pitofenone,
Fenperinium and
NSAID"
180/CAL/1996
Vasoconstrictive Substituted 2,3-Dihydro-1,4 Dioxinopyridines.
Janseen Pharmaceutica N.V.
11/CAL/2000
A Process For Preparing A Novel Formulation Used As A Feed Additive For Type II Diabetes
1019/MUMNP/2
IN/PCT/2001/00
483/MUM
A Method For Preparing 3, 3- Disubstituted 1 -
Amino-2- Hydroxypropanes
117/MUM
An Isolated Nucleic Acid Molecule Encoding A Human Nerotrophic Growth Factor
Janssen Pharmaceuti
Ca N. V.
1276/DEL/2002
"A Process of Synthesizing High Quantities Of Human Interferon Alpha 2a Protein"
Jyoti Mukherjee, Poonam Srivastava,P
641/DEL/2000
"A Pharmaceutical Composition Based
on Nanoparticles of Polymeric Michelles Containing Paclitaxel"
1163/DEL/2000
"Novel Substituted 1hbenz[ De]Isoquinolin
E-1,3-Diones"
Council of Scientific
339/MUMNP/20
Quinolinecarboxylic Acid Derivative or Salts Thereof
Wakunaga Pharmaceutical Co., Ltd
"A Pharmaceutical
Control And Prevention of Anorectal and Colonic Diseases"
Posted by Priyank on 10:48:00 PM 1 comment:
Suven Life Sciences gets two European patents
India-based Suven Life Sciences Ltd said the European Patent Office has granted patents for two of Suven's compounds (EP1523486 B1 & EP1581538 B1) TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, aimed at treating cognitive impairments associated with neurodegenerative disorders like Alzheimer's, Parkinson's disease and schizophrenia.
The compounds are being developed as therapeutic agents and the patents are valid until June 2022, the company said in a filing to India's National Stock Exchange.
Posted by Priyank on 1:24:00 AM No comments:
Cobalt Eyes AstraZeneca’s Blockbuster Cholesterol Drug
In a major development, the Canadian drug manufacturer Cobalt Pharmaceuticals stunned AstraZeneca by making Paragraph IV certification against Astra’s money-spinning cholesterol drug Crestor which worth US $ 2 billion in a process for submission of an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking regulatory approval to market generic version of Crestor, generically known as rosuvastatin calcium, before the expiration of Astra’s Orange Book listed patents valid till 2021. AstraZeneca has 45-day statutory period under the Hatch-Waxman provision for deciding to initiate an infringement action and halting FDA from approving the generic version for at least 30 months. AstraZeneca has three patents listed with the Orange Book including composition-of-matter patent. In its notice to Astra, Cobalt intended market generic version of Crestor before the expiration of US Patent Nos. RE 37, 314 (the ‘314 patent) and 6,316,460 (the ‘460 patent) alleging that the claims of the ‘314 and ‘460 patents are not infringed, invalid or unenforceable. Also stated that its ANDA contains a certification under section 505(j)(2)(A)(viii) of the FDCA alleging that its labeling will not include medical uses claimed in the US Patent No. 6,858,618 (the ‘618 patent). The ‘314 patent expires in January 2016, the ‘460 patent expires in August 2020, and the ‘618 patent expires in December 2021.
Posted by Varun Chhonkar on 9:32:00 AM No comments:
Avestha Files Indian Patent Applications for DPP i...
PCT Application for Ritonavir Polymorph Enters Ind...
Granted patents in India on November 23, 2007 (Pha...
Cobalt Eyes AstraZeneca’s Blockbuster Cholesterol ...